Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07743242
Recruiting Not applicable

Autoimmune Hemolytic Anemia and Its Clinical Implication on Antiphospholipid Syndrome

NCT07743242 · tracked via the Priya Life Science Egypt tracker
Sponsor
New Valley University
Phase
Not applicable
Started
2026-06-05
Last updated
2026-08-10

Condition(s) studied

Anti Phospholipid Syndrome

Investigational drug(s) / intervention(s)

HemoglobinCoombs test

Hemoglobin: Blood sample

Coombs test: Blood sample

Study summary

AIHA is a heterogeneous autoimmune cytopenia with variable severity and significant morbidity. APS is defined by thrombosis and/or obstetric morbidity with persistent antiphospholipid antibodies (aPL).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults aged ≥18 years * Patients with anemia consistant with hemolysis. * Patient diagnosed with antiphospholipid syndrome. * Informed consent obtained Exclusion Criteria: * Age less than 18 years. * Other causes of anemia than autoimmune hemolysis.

Primary outcome measure(s)

  • Number of thrombotic events in APS patients with AIHA — baseline

Trial sites (1)

FacilityCityRegionStatus
New Valley University Al Khārjah Kharga Oasis Recruiting

More New Valley University trials in Egypt

Thrombocytopenia Trajectories in Antiphospholipid Syndrome: A Multicenter Cohort Study Recruiting
Can COX-2 Inhibitor Decrease Stricture Recurrence After Direct Vision Internal Urethrotomy? Recruiting
Causes of Visual Impairment Among Patients Applying for the Visually Disability Certification Active, not recruiting
Retroclavicular Block in Vascular Surgey Recruiting
Novel Transdermal Ketoprofen Gel Formulation for Knee Osteoarthritis Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07743242 on ClinicalTrials.gov ↗ ← All trials in Egypt